Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

Shanghai: U.S. President Donald Trump on Thursday unveiled a 100% tariff on imports of branded drugs from October 1, unless their producers had already broken ground on U.S. manufacturing plants . The European Union and Japan expressed confidence on Friday that they had secured limits on U.S. tariffs on pharmaceuticals . Below are some of the patented medicines from Asian and European drugmakers imported into the U.S. from overseas manufacturing sites in countries including China, Switzerland, Japan, Belgium and France, according to analysts and drugmaker statements. Lenvima Japan's Eisai's cancer drug Lenvima is manufactured in Japan, J.P.Morgan wrote in a recent note. Its US sales for the fiscal year ending March 31, 2025 were 229.6 billion yen ($1.53 billion). The company's US manufacturing site in Baltimore, Maryland, is responsible for producing a biodegradable implant used during surgeries, according to its website. Crystvita Kyowa Kirin 's X-linked hypophosphataemia drug Crysvita is manufactured in Japan, according to J.P.Morgan. In North America, the drug generated more than $1.3 billion net sales in its first four years on the market. It is building a biologics manufacturing facility in Sanford, North Carolina. Shingrix GSK 's vaccine Shingrix, used to prevent shingles, contributed 3.36 billion pounds ($4.50 billion) in sales in 2024. Its ingredients are manufactured in Belgium according to product labelling information provided in the National Institutes of Health platform and the U.S. FDA platform. Arexvy Arexvy is a vaccine developed by GSK to protect against Respiratory Syncytial Virus (RSV) in adults. It contributed 590 million pounds in sales in 2024. Its ingredients are made in Belgium and France according to product labelling information, given in NIH and U.S. FDA websites. Ozempic Novo Nordisk 's diabetes drug, Ozempic, contributed 120.34 billion DKK ($18.85 billion) in sales in 2024. It is manufactured in Denmark, according to the product labelling information given in NIH. In April, Novo Nordisk said it will invest 6.4 billion reais ($1.20 billion) in Brazil to boost production. The factory will cater to various product formats, including GLP-1 medicines such as semaglutide, the active ingredient in Ozempic and Wegovy. Wegovy Novo Nordisk's weightloss drug, Wegovy, contributed 58.21 billion DKK in sales in 2024. It is manufactured in Denmark, according to the product labelling information given in NIH. Kymriah Swiss drugmaker Novartis ' cell therapy Kymriah is manufactured at its Stein site in Switzerland and at its U.S. facility in Morris Plains, New Jersey, which produces CAR-T therapies for individual patients and clinical trials, according to the company's website. Its global sales for the first half of 2025 were $199 million. Entresto Novartis' heart-failure medicine Entresto is produced at Novartis manufacturing sites globally, with key stages of production taking place in Switzerland. Its global sales for the first half of 2025 were $4.62 billion. Novartis announced a $23 billion investment in April to build and expand 10 facilities in the U.S., including six new manufacturing plants and a research hub in San Diego. Comirnaty Germany's BioNTech and Pfizer co-developed COVID-19 vaccine Comirnaty. It is manufactured at BioNTech sites in Mainz and Marburg, Germany, and at Pfizer's facility in Puurs, Belgium, according to the company. BioNTech is the Marketing Authorization Holder for COMIRNATY and its adapted vaccines in the US, the EU, the UK and other countries. (Sources: NIH, FDA, company websites, company press releases, analyst notes)

Around 300,000 more people will become eligible for a potentially lifesaving shingles vaccination from next week, as GP practices roll out the jab to protect all severely immunosuppressed adults. People newly eligible for the shingles vaccination from Monday 1 September are those aged 18 to 49 who have a severely weakened immune system. They will be able to book an appointment for the vaccine with their GP surgery, with practices starting to contact people over the coming weeks. This includes people with conditions such as leukaemia or lymphoma or those who are undergoing chemotherapy, which put them at greater risk of becoming seriously unwell if they contract shingles. The NHS has previously expanded the shingles vaccination programme to include all over 50s with a severely weakened immune system. Patient organisations welcome the latest expansion that will see thousands more at risk people protected. Shingles is caused by the reactivation of the varicella zoster virus (which causes chickenpox) and usually occurs decades after initial infection. The condition causes a painful rash and typically lasts between 2 and 4 weeks. 1 in 5 people will go on to develop shingles in their lifetime and although most people make a full recovery, it can cause serious problems including persistent pain known as post-herpetic neuralgia, eye problems, and even lead to pneumonia, hepatitis and inflammation of the brain. Individuals who are severely immunosuppressed are most at risk of serious illness and complications from shingles. The vaccine, Shingrix®, is currently available to people aged 65 to 79 and severely immunosuppressed individuals from 50 years of age, but eligibility is set to change from next week to include all severely immunosuppressed adults aged 18 years and over. The roll out to all severely immunosuppressed adults follows advice from the Joint Committee on Vaccination and Immunisation (JCVI) who found that the risk of hospitalisation from shingles or those resulting in post-herpetic neuralgia was similar in younger immunosuppressed age groups to those who were already eligible. Dr Amanda Doyle, National Director for Primary Care and Community Services at NHS England, said: “Shingles can be seriously debilitating for older people and those with a severely weakened immune system, so following the latest expert guidance, the NHS is now expanding the potentially lifesaving jab to all severely immunosuppressed adults. “The vaccine is safe and effective and significantly reduces the chance of developing shingles and becoming seriously unwell, so I’d urge anyone newly eligible to come forward for their protection as soon as possible. “The NHS will be contacting you to let you know you are eligible, but you can also make a booking through your local GP – and even if you’ve had shingles before, you can develop it again so please still come forward for the offer”. Health Minister Ashley Dalton said: “Expanding shingles vaccination will protect even more people at greatest risk from this painful condition. “This government is committed to preventive healthcare and ensuring those who are most vulnerable receive the protection they need. “I encourage all those eligible for the vaccine to come forward for their jab”. Severely immunosuppressed people will be offered 2 doses of the non-live shingles vaccine, Shingrix®, with the second dose given 8 weeks to 6 months after the first dose. A JCVI report estimates that prior to the introduction of a shingles vaccination programme in 2013, there were over 4,500 hospital admissions per year due to shingles, most of which could have been prevented through vaccination. Within the first 3 years of the vaccination programme, there were an estimated 17,000 fewer episodes of shingles and 3,300 fewer episodes of post-herpetic neuralgia among the eligible population. Dr Gayatri Amirthalingam, Deputy Director of Immunisation at the UK Health Security Agency: “Shingles can be a very painful infection and may cause complications that lead to hospitalisation. It can affect people at any age, but the risk and severity of shingles increases with age. However, following a review of the evidence, it was found that younger adults who are severely immunosuppressed are also at higher risk of severe illness and hospitalisation, and from September the shingles vaccine programme will now be expanded to include this group who are aged 18 and over. “The NHS will continue a phased roll out of the vaccine for older people and your GP should be in touch once you become eligible, currently when you reach 65 or 70 years. “Shingles can be a nasty, painful disease, so I strongly recommend you have the vaccine, given as 2 doses, as soon as you become eligible, and if you are unsure, please do check with your GP surgery”. NHS services were contacted about the expansion in July to ensure that they are ready to roll out the vaccine from September, and Shingrix® can be given alongside other seasonal and routine vaccines, including flu and COVID-19. Susan Walsh, Chief Executive Officer of Immunodeficiency UK, said: “We welcome the widening of the age eligibility criteria for the shingles vaccination programme for immunosuppressed individuals. It means that people most at risk will be able to have protection against the worst effects of having shingles and will help reduce the risk of being hospitalised from its complications. We are encouraging everyone eligible to take up the offer”. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.